Precision cancer management for improved patient care

Precision medicine demands precision instruments

Advances in medical imaging and the introduction of screening programs have resulted in the increased detection of small tumors. At the same time, new treatment paradigms and the emerging era of precision medicine increase demands on tissue quality and quantity. New biopsy technologies are needed to address these challenges by obtaining samples with precision, control and minimal patient trauma.

Introducing NeoNavia - A new level of control in breast biopsy

The NeoNavia biopsy system is clinically tested and designed to deliver quality samples – no matter how challenging the case.

learn more

Innovative micropulse technology

NeoNavia utilizes a pneumatic needle insertion mechanism that allows for controlled needle progression with incremental insertion. This micropulse technology enables controllable and precise needle insertion independent of tissue characteristics.

6million

breast biopsies are performed every year

10%

annual increase in breast biopsy procedures

Breast cancer management is evolving

Despite major improvements in medical imaging and breast cancer treatment, little has changed in recent decades when it comes to breast biopsy technology — a key enabler of high-quality breast cancer care. NeoNavia was developed to address the need for a breast biopsy device better suited to the era of precision medicine.

Enabling precision medicine

Targeted therapy starts with adequate and appropriate tumor tissue samples. To meet the needs of today’s clinicians and patients, a precision biopsy tool is needed to enable confident sampling in even the most challenging cases.

NeoNavia was developed with this in mind, combining:

High-precision control of needle insertion and positioning
Safe and flexible lesion targeting in challenging sites
Maximum tissue yield regardless of lesion size
learn more about NeoNavia

“The NeoNavia biopsy device can safely increase the precision of ultrasound-guided core biopsy of ”technically difficult” lesions, including deep axillary lymph nodes. It would also be suitable for ultrasound-guided biopsy of small breast lesions and lesions close to the chest wall.”

J. Lee, B. Bishop, S. Allen; The Royal Marsden NHS Foundation Trust, London; Oxford University Hospitals NHS Foundation Trust, Oxford, UK; Published in Breast Cancer Research 2017, 19(Suppl 1):PB.39

"The uncontrolled rapid needle movement of today’s most common biopsy methods bears the risk of side effects such as injuring relevant anatomical structures. By contrast, NeoNavia’s innovative design combines maximum sampling efficiency with complete control of the biopsy needle movement in every phase of the procedure”

Dr. med. Stefan Paepke, Senior physician Breast Centre, Women’s Hospital, Rechts der Isar der Technischen Universität München (TUM) Germany

NeoDynamics is a privately owned Swedish medical technology company based on research conducted at the renowned Karolinska Institutet.

learn more about us